Rebecca Silbermann is a Hematology physician affiliated with Oregon Health & Science University. OpenAlex indexes 153 publications with 3,346 citations (h-index 26); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd
Portland, OR 972393011
Telephone
503-494-5058Registry record last updated 19 Jul 2017.
Clinical trials
- Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
Sponsor: OHSU Knight Cancer Institute
- A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma
Sponsor: Rebecca Silbermann
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20253 payments
- Janssen Scientific Affairs, LLCProgram year20253 payments
- Janssen Biotech, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
34.2%Thalidomide Analog30%Lenalidomide45%Revlimid39%Pomalyst16%Part D<11 patientsBCL-2 Inhibitor2.9%Venclexta100%Part D<11 patients+ 1 more class in this area
Dermatology
27.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor27.5%Acyclovir100%Part D≥60 patientsNervous system
15.2%Gabapentinoids4.5%Gabapentin63%Pregabalin37%Part D<11 patientsOpioid Agonist3.6%Oxycodone Hcl100%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”